Scheessele William John 4
4 · Humacyte, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Scheessele William John
Chief Commercial Officer
Transactions
- Award
Stock Options (right to buy)
2021-10-13+157,558→ 157,558 totalExercise: $10.03Exp: 2031-10-13→ Common Stock (157,558 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on August 9, 2022, after which 1/36 of the option will become exercisable on the 9th of each month through August 9, 2025.